Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review
- PMID: 38405003
- PMCID: PMC10891406
- DOI: 10.21037/tlcr-23-744
Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review
Abstract
Background and objective: The role of biological sex is seldom considered in characterizing lung cancer, the deadliest cancer in both the United States and the world. Lung cancer has traditionally been regarded as a male disease; as such, research in female-specific phenomena is frequently conflicting or absent. Currently, disparities in lung cancer incidence are primarily driven by females, especially non-smokers and those of younger age. This narrative review provides insight into sex-specific characteristics of lung cancer, highlighting risk factors, diagnosis patterns, carcinogenesis, and treatment outcomes in females.
Methods: The PubMed database was searched on July 26, 2023 to identify research published between 2013 and 2023 in English. Sixty-three articles were considered relevant, and their full texts and citations were studied to compile information for this narrative review.
Key content and findings: Exposure-related risk factors, including personal tobacco use, are thought to impact female lung cancer risk more profoundly. However, studies on occupational exposures are underpowered to conclude risk in females. Data characterizing the effect of endogenous and exogenous hormonal exposures on female lung cancer risk remain two-sided. Screening guidelines are tailored to white males, exacerbating sex and race disparities. The effect of biological sex on carcinogenesis and the immune system response to cancer is not fully understood, though the female immune system clearly reacts more aggressively to lung cancer. In early-stage disease, females have greater survival in the perioperative setting and during follow-up of several years, attributed to favorable histopathology and healthier baseline status. Sex-specific response to systemic treatment continues to be optimized as lack of standardization in randomized trials makes interpreting results difficult when aggregated.
Conclusions: Biological sex plays a critical role in non-small cell lung cancer (NSCLC), though further study is needed to depict the complex web of factors that affect lung cancer risk, development, and outcomes. Female underrepresentation in studies has contributed to this lack of understanding. As these disparities are eliminated, we can move towards more effective treatment for both sexes in this pervasive yet deadly disease.
Keywords: Lung cancer; female; non-small cell lung cancer (NSCLC); sex; sex difference.
2024 Translational Lung Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/coif). S.Y. is a scientific advisory board member of Karkinos Healthcare, receives grant funding from Lumeda Inc., and serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2023 to September 2025. The other author has no conflicts of interest to declare.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).Natl Toxicol Program Tech Rep Ser. 1993 Sep;421:1-287. Natl Toxicol Program Tech Rep Ser. 1993. PMID: 12616290
-
Telephone interventions for symptom management in adults with cancer.Cochrane Database Syst Rev. 2020 Jun 2;6(6):CD007568. doi: 10.1002/14651858.CD007568.pub2. Cochrane Database Syst Rev. 2020. PMID: 32483832 Free PMC article.
-
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].Epidemiol Prev. 2023 Jan-Apr;47(1-2 Suppl 1):1-286. doi: 10.19191/EP23.1-2-S1.003. Epidemiol Prev. 2023. PMID: 36825373 Italian.
Cited by
-
Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiological technologists.J Natl Cancer Inst. 2025 Jul 1;117(7):1429-1437. doi: 10.1093/jnci/djaf064. J Natl Cancer Inst. 2025. PMID: 40112244 Free PMC article.
-
Chitosan gold nanogel containing Rova-Typhoid immunotoxins against the DLL3 receptor has a promising effect on small-cell lung cancer.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 2. doi: 10.1007/s00210-025-04321-6. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40455231
-
Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye.Med Sci Monit. 2025 Apr 1;31:e947817. doi: 10.12659/MSM.947817. Med Sci Monit. 2025. PMID: 40165351 Free PMC article.
-
Sex-Based Differences in Lung Cancer Incidence: A Retrospective Analysis of Two Large US-Based Cancer Databases.Cancers (Basel). 2024 Sep 24;16(19):3244. doi: 10.3390/cancers16193244. Cancers (Basel). 2024. PMID: 39409866 Free PMC article.
-
Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile.Front Immunol. 2025 Jun 19;16:1602579. doi: 10.3389/fimmu.2025.1602579. eCollection 2025. Front Immunol. 2025. PMID: 40612952 Free PMC article.
References
-
- World Health Organization. Lung cancer. 2023. Accessed July 25, 2023. Available online: https://www.who.int/news-room/fact-sheets/detail/lung-cancer
-
- World Health Organization. Cancer. 2022. Accessed July 25 2023. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer
-
- U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2023. Accessed January 5, 2024. Available online: https://www.cdc.gov/cancer/dataviz
-
- Cancer Facts & Figures 2023. Atlanta: American Cancer Society, Inc.; 2022. Accessed January 9, 2024. Available online: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-...
Publication types
LinkOut - more resources
Full Text Sources
Research Materials